Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations

S. Ii, S. Minnerath, K. Ii, Peter J Dyck, S. S. Sommer

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We analyzed 11 consecutive unrelated cases of polyneuropathy due to transthyretin amyloidosis. Direct sequencing of the promoter region, exons, and splice junctions revealed that each patient was heterozygous for a mutation: six patients had valine 30 substituted by methionine (V30 → M; Portuguese-Japanese type), one had threonine 60 substituted by alanine (T60 → A; Appalachian type), and two had serine 77 substituted by tyrosine (S77 → Y; Illinois type). In addition, two patients had previously undescribed mutations: phenylalanine 33 substituted by leucine (F33 → L) and phenylalanine 64 substituted by leucine (F64 → L). From present information, the probands of these novel mutations do not exhibit any pathology that clearly distinguishes them from individuals with the other mutations. The mutations extend the range of mutations associated with amyloidotic polyneuropathy. In our 11 patients, the different mutations did not seem to correlate with distinct clinical phenotypes. We developed PASA assays (PCR amplification of specific alleles) for each of the five mutations. PASA can be used by any diagnostic laboratory that can perform PCR to rapidly detect any of the known mutations. The minority of samples with an undescribed mutation can be sent to a specialty laboratory for delineation of the mutation by direct genomic sequencing. The presently described combination of methods may have widespread utility in the diagnosis of genetic disease.

Original languageEnglish (US)
Pages (from-to)893-898
Number of pages6
JournalNeurology
Volume41
Issue number6
StatePublished - 1991

Fingerprint

Point Mutation
Mutation
DNA
Polyneuropathies
Phenylalanine
Leucine
Amyloidosis, Hereditary, Transthyretin-Related
Polymerase Chain Reaction
Inborn Genetic Diseases
Valine
Threonine
Genetic Promoter Regions
Alanine
Methionine
Serine
Tyrosine
Exons
Alleles
Pathology
Phenotype

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations. / Ii, S.; Minnerath, S.; Ii, K.; Dyck, Peter J; Sommer, S. S.

In: Neurology, Vol. 41, No. 6, 1991, p. 893-898.

Research output: Contribution to journalArticle

Ii, S, Minnerath, S, Ii, K, Dyck, PJ & Sommer, SS 1991, 'Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations', Neurology, vol. 41, no. 6, pp. 893-898.
Ii, S. ; Minnerath, S. ; Ii, K. ; Dyck, Peter J ; Sommer, S. S. / Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations. In: Neurology. 1991 ; Vol. 41, No. 6. pp. 893-898.
@article{de4ccf5f3dac4436b2c0d74e48998276,
title = "Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations",
abstract = "We analyzed 11 consecutive unrelated cases of polyneuropathy due to transthyretin amyloidosis. Direct sequencing of the promoter region, exons, and splice junctions revealed that each patient was heterozygous for a mutation: six patients had valine 30 substituted by methionine (V30 → M; Portuguese-Japanese type), one had threonine 60 substituted by alanine (T60 → A; Appalachian type), and two had serine 77 substituted by tyrosine (S77 → Y; Illinois type). In addition, two patients had previously undescribed mutations: phenylalanine 33 substituted by leucine (F33 → L) and phenylalanine 64 substituted by leucine (F64 → L). From present information, the probands of these novel mutations do not exhibit any pathology that clearly distinguishes them from individuals with the other mutations. The mutations extend the range of mutations associated with amyloidotic polyneuropathy. In our 11 patients, the different mutations did not seem to correlate with distinct clinical phenotypes. We developed PASA assays (PCR amplification of specific alleles) for each of the five mutations. PASA can be used by any diagnostic laboratory that can perform PCR to rapidly detect any of the known mutations. The minority of samples with an undescribed mutation can be sent to a specialty laboratory for delineation of the mutation by direct genomic sequencing. The presently described combination of methods may have widespread utility in the diagnosis of genetic disease.",
author = "S. Ii and S. Minnerath and K. Ii and Dyck, {Peter J} and Sommer, {S. S.}",
year = "1991",
language = "English (US)",
volume = "41",
pages = "893--898",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations

AU - Ii, S.

AU - Minnerath, S.

AU - Ii, K.

AU - Dyck, Peter J

AU - Sommer, S. S.

PY - 1991

Y1 - 1991

N2 - We analyzed 11 consecutive unrelated cases of polyneuropathy due to transthyretin amyloidosis. Direct sequencing of the promoter region, exons, and splice junctions revealed that each patient was heterozygous for a mutation: six patients had valine 30 substituted by methionine (V30 → M; Portuguese-Japanese type), one had threonine 60 substituted by alanine (T60 → A; Appalachian type), and two had serine 77 substituted by tyrosine (S77 → Y; Illinois type). In addition, two patients had previously undescribed mutations: phenylalanine 33 substituted by leucine (F33 → L) and phenylalanine 64 substituted by leucine (F64 → L). From present information, the probands of these novel mutations do not exhibit any pathology that clearly distinguishes them from individuals with the other mutations. The mutations extend the range of mutations associated with amyloidotic polyneuropathy. In our 11 patients, the different mutations did not seem to correlate with distinct clinical phenotypes. We developed PASA assays (PCR amplification of specific alleles) for each of the five mutations. PASA can be used by any diagnostic laboratory that can perform PCR to rapidly detect any of the known mutations. The minority of samples with an undescribed mutation can be sent to a specialty laboratory for delineation of the mutation by direct genomic sequencing. The presently described combination of methods may have widespread utility in the diagnosis of genetic disease.

AB - We analyzed 11 consecutive unrelated cases of polyneuropathy due to transthyretin amyloidosis. Direct sequencing of the promoter region, exons, and splice junctions revealed that each patient was heterozygous for a mutation: six patients had valine 30 substituted by methionine (V30 → M; Portuguese-Japanese type), one had threonine 60 substituted by alanine (T60 → A; Appalachian type), and two had serine 77 substituted by tyrosine (S77 → Y; Illinois type). In addition, two patients had previously undescribed mutations: phenylalanine 33 substituted by leucine (F33 → L) and phenylalanine 64 substituted by leucine (F64 → L). From present information, the probands of these novel mutations do not exhibit any pathology that clearly distinguishes them from individuals with the other mutations. The mutations extend the range of mutations associated with amyloidotic polyneuropathy. In our 11 patients, the different mutations did not seem to correlate with distinct clinical phenotypes. We developed PASA assays (PCR amplification of specific alleles) for each of the five mutations. PASA can be used by any diagnostic laboratory that can perform PCR to rapidly detect any of the known mutations. The minority of samples with an undescribed mutation can be sent to a specialty laboratory for delineation of the mutation by direct genomic sequencing. The presently described combination of methods may have widespread utility in the diagnosis of genetic disease.

UR - http://www.scopus.com/inward/record.url?scp=0025892926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025892926&partnerID=8YFLogxK

M3 - Article

C2 - 2046936

AN - SCOPUS:0025892926

VL - 41

SP - 893

EP - 898

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -